The global lysosomal alpha glucosidase market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Lysosomal alpha glucosidase is termed as a recombinant enzyme used to treat lysosomal storage disorder known as Pompe disease (which is also known by the name acid maltase deficiency or glycogen storage disease type II). Pompe disease is perceived as an inherited fatal muscular myopathy disorder caused due to the glycogen build-up in the body cells such as in cardiac, smooth, and skeletal muscle cells. The disease is further characterized by the absence and in some cases, deficiency of the lysosomal enzyme alpha-glucosidase. The market growth is majorly driven by the growing research coupled with the increasing clinical trials that ensures a robust product pipeline for the future years.
To Request a Sample of our Report on Lysosomal Alpha Glucosidase Market: https://www.omrglobal.com/request-sample/lysosomal-alpha-glucosidase-market
Key players such as Sanofi have already initiated the clinical trials which spurred the market growth. For instance, in 2016, in order to treat Pompe disease, Genzyme, a unit of Sanofi, started phase III clinical trial for NeoGAA, a second generation alglucosidase alfa enzyme-based enzyme replacement therapy. Further, in 2017, Valerion Therapeutic, a clinical-stage biotechnology company specialized in the development of therapies for orphan genetic diseases, initiated phase I/II clinical trials for its candidate drug, VAL-1221 in patients with late-onset of Pompe disease. VAL-1221 combines company’s proprietary antibody-mediated delivery technology with recombinant human acid alpha-glucosidase, offering improved glycogen clearance and better patient outcomes. In February 2018, a biotechnology company named Audentes Therapeutics, Inc. conducted phase I/II clinical trial for AT982 for commercializing and developing gene therapy products to treat Pompe disease.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Product
- By Distribution Channel
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: Amicus Therapeutics Inc., and Sanofi SA, among others.
(Get 15% Discount on Buying this Report)
A full Report of Lysosomal Alpha Glucosidase Market is Available @ https://www.omrglobal.com/industry-reports/lysosomal-alpha-glucosidase-market
Global Lysosomal Alpha Glucosidase Market Report by Segment
By Product
- Myozyme
- Lumizyme
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Global Lysosomal Alpha Glucosidase Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
